To test for the relative contributions of the dopaminergic and serotoninergic systems in the striatum to the effects of d-fenfluramine, an indirect serotonin receptor agonist, we assessed the expression of Fos/Jun proteins induced by d-fenfluramine given alone or in the presence of dopaminergic or serotoninergic agents. To determine the neuronal targets of d-fenfluramine in the striatum, we identified the phenotypes of striatal neurons in which d-fenfluramine induced Fos expression. Our results demonstrated that d-fenfluramine evokes nuclear expression of Fos/Jun B proteins in the striatum, and that the Fos expression was dose-dependent and accompanied by transient induction of c-fos mRNA. Fos expression was blocked by p-chloroamphetamine, a serotoninergic neurotoxin. Pretreatment with SCH 23390, a D 1 -dopamine receptor antagonist, led to a marked decrease in Fos/Jun B expression in the caudoputamen, but not in the cortex, whereas pretreatment with methiothepin, a nonselective serotonin 5-HT 1 receptor antagonist, blocked Fos expression completely in the cortex and only partially in the caudoputamen. The expression of Fos/Jun B in the striatum occurred mainly in dynorphincontaining neurons and in a subpopulation of striatal interneurons that exhibited NADPH-diaphorase activity. Most of the enkephalin-containing neurons of the striatum did not show Fos/Jun B staining. These results suggest that the mechanism by which d-fenfluramine induces c-fos and jun B expression in the rat caudoputamen depends at least in part on activation of the dopaminergic system by serotonin.
The innovative method for mapping neuronal activity by monitoring the nuclear expression of immediate-early genes (IEGs) has proven to be particularly successful in identifying selective neuroanatomical loci targeted by drugs (Hughes and Dragunow, 1995) . We have used this method to approach the question of what neurotransmitter receptors are responsible for the activation of IEGs in the striatum following an acute exposure to d-fenfluramine. d-Fenfluramine acts both by releasing serotonin [5-hydroxytryptamine (5-HT)] from nerve terminals and by blocking 5-HT reuptake (Samanin and Garattini, 1990; Appel et al., 1991) . Evidence suggests that most of the behavioral effects of this drug, including stimulation of the hypothalamo-pituitary-adrenal axis, decrease in food intake by enhancing satiety, and increase in thermogenesis, are mediated through the activation of brain serotoninergic systems. d-Fenfluramine has been shown in in vivo microdialysis studies to increase extracellular 5-HT levels in the caudoputamen and nucleus accumbens, as well as in the frontal cortex and hypothalamus (Laferrere and Wurtman, 1989; Balcioglu and Wurtman, 1998) . All of these effects of d-fenfluramine have also been observed with d,l-fenfluramine, the racemic mixture of the d and l isomers of fenfluramine (Auerbach et al., 1989; Sabol et al., 1992; Kirby et al., 1995) .
Immunohistochemical studies have shown that Foslike proteins are expressed rapidly and transiently in specific regions of the rat brain following a single administration of d-fenfluramine to rodents (Li and Rowland, 1993; Li et al., 1994) . Consistent with the serotoninergic-related behavioral effects of d-fenfluramine, the brain regions showing the most intense Fos immunostaining include regions receiving a dense serotonin-ergic innervation from raphe nuclei, such as several nuclei of the hypothalamus and the lateral parabrachial nucleus. The striatum, however, may differ from other brain regions, because the close parallels between the pharmacological effects of d-fenfluramine and d,l-fenfluramine have not been found for the striatal induction of Fos-like proteins. A single systemic administration of the racemic mixture d,l-fenfluramine at a dose lower than 20 -25 mg/kg fails to induce the nuclear expression of Fos-like proteins in the rat striatum (Richard et al., 1992; Torres and Rivier, 1993, 1994; Torres, 1995; Rouillard et al., 1996; Cook and Wirtshafter, 1998) . By contrast, the d isomer, d-fenfluramine, appears more efficient in activating striatal neurons to express Fos-like proteins, because it induces Fos in the striatum even at very low doses (2-3 mg/kg) in rats (Li and Rowland, 1993) . This paradoxical result is surprising given that the d isomer, d-fenfluramine, is thought to act mainly on serotoninergic neurons, whereas the racemic mixture d,l-fenfluramine contains 50% of the l isomer, which can directly release dopamine (Jori and Bernardi, 1972; Garattini et al., 1975; Crunelli et al., 1980; Invernizzi et al., 1986; Bettini et al., 1987) . Given that the striatum receives a massive dopaminergic innervation from the substantia nigra pars compacta along with its dense serotoninergic input from the dorsal raphe nucleus (Steinbusch, 1984) , a robust induction of Fos would have been predicted following the direct release of dopamine by d,l-fenfluramine.
Here we examined the possibility that d-fenfluramine triggers transcription factor gene expression in the striatum as an indirect consequence of interactions between striatal 5-HT and dopamine circuitries. Such an action of d-fenfluramine could reflect the major known pharmacological actions of d-fenfluramine, i.e., the enhanced release and decreased reuptake of endogenous 5-HT. The 5-HT in turn could stimulate the release of dopamine in the striatum, leading to the expression of Fos-like proteins in striatal neurons. Serotoninergic neurons of the midbrain raphe nuclei have been shown to modulate dopaminergic nigrostriatal pathways (Soubrié et al., 1984; Yadid et al., 1994) , and an in vivo microdialysis study has demonstrated an indirect dopamine-releasing capacity of d-fenfluramine, secondary to its ability to release 5-HT in the striatum (Balcioglu and Wurtman, 1998) .
To test for the relative contributions of the dopaminergic and serotoninergic systems in the striatum to the effects of d-fenfluramine, we assayed d-fenfluramineinduced expression of Fos/Jun proteins in the striatum across a range of doses of the drugs (5, 10, 20, or 40 mg/kg). We then tested for this expression of Fos/Jun proteins when d-fenfluramine was given in the presence of agents that interfere with dopaminergic or serotoninergic neurotransmission. Finally, we studied the neuronal targets of d-fenfluramine in the striatum by identifying the phenotypes of striatal neurons in which d-fenfluramine induced Fos expression.
EXPERIMENTAL PROCEDURES

Animals and experimental design
Adult male Sprague-Dawley rats (180 -200 g) were used in this study. Animals were housed with a 12-h light/dark cycle with free access to food and water. Drugs were dissolved in 0.9% NaCl except for methiothepin, which was dissolved in 4% polyethylene glycol in 0.9% NaCl and were given intraperitoneally in a volume of 2 ml/kg. On the day of the experiment, the rats were brought into a quiet experimental room and the drugs were administered at the following doses (Table 1) : d-fenfluramine hydrochloride (Servier Laboratories, Neuillysur-Seine, France), 5, 10, 20, and 40 mg/kg; cocaine hydrochloride (Sigma), 25 mg/kg as previously described (Moratalla et al., 1993) 
Immunohistochemistry
Two hours following drug treatment, rats were deeply anesthetized with pentobarbital (1 ml/kg; Sanofi Santé Nutrition Animale, Libourne, France) and were then perfused transcardially with 0.9% NaCl followed by 4% paraformaldehyde in 0.1 M sodium phosphate buffer containing 0.9% NaCl (PBS), pH 7.4. Brains were removed and cut coronally at 30 m on a sliding microtome. Single antigen immunostaining was performed on free-floating sections (Graybiel et al., 1990) , with a standard avidin-biotin peroxidase complex (ABC protocol, Vectastain, Vector Laboratories, Burlingame, CA, U.S.A.). The sections were pretreated with 3% H 2 O 2 and 0.3% Triton X-100 in PBS for 10 min and with 5% normal goat serum for 30 min. Incubations in primary antisera were carried out overnight at 4°C. The sections were then incubated successively in biotin- Doses (in mg/kg of body weight, i.p.) and schedule of treatments are given. The standard series were d-fenfluramine with 2-h survival time (D). For combined-drug treatments, times before final d-fenfluramine were 30 min each for the selective D 1 receptor antagonist, SCH 23390, and for the nonselective 5-HT 1 receptor antagonist, methiothepin, and once a day for 5 days (7.5 mg/kg daily for 2 days and then 10 mg/kg daily for 3 days) for the neurotoxin PCA. In control experiments, SCH 23390 and methiothepin were also given individually at the doses indicated for the combined-drug experiments.
a Number in parentheses indicates animals given alternative dose shown in parentheses in the middle column. ylated goat anti-rabbit IgG diluted 1:500 (Vector) for 1 h and in avidin-biotin peroxidase complex (Vector) for 1 h, and then were treated with 0.0001% H 2 O 2 and 0.08% nickel ammonium sulfate (Farmitalia Carlo Erba Analyticals) and 0.02% 3,3Ј-diaminobenzidine (Sigma) as chromogen. Each step was preceded by washes in 0.01 M PBS. Sections were mounted on gelatin-coated slides, air-dried, dehydrated, coverslipped with Permount, and analyzed by light microscopy.
Some sections were also processed by a double-labeling technique to study the distribution of Fos-like immunoreactivity in NADPH-diaphorase interneurons. In the rat striatum, NADPH-diaphorase activity had been shown largely to coincide with the type I isoform of the enzyme nitric oxide synthase, which is the isoform constitutively expressed in neurons (i.e., neuronal nitric oxide synthase) (Dawson et al., 1991) . Thus, for nitric oxide synthase-containing interneurons, sections were first immunostained by the ABC protocol and then were reacted for NADPH-diaphorase activity (Moratalla et al., 1996a) .
Dual antigen immunohistochemistry was carried out to study the distribution of Fos/Jun B in dynorphin-or enkephalinpositive projection neurons in the striatum. Sections were first stained for Fos or Jun B as indicated above, but using 3,3Ј-diaminobenzidine alone. Then a second staining with the second antibody (anti-dynorphin or anti-enkephalin) was carried out with 3,3Ј-diaminobenzidine and nickel ammonium sulfate as chromophore (Moratalla et al., 1996a) .
Antisera
To detect Fos-Jun family proteins, we used polyclonal rabbit antisera against c-Fos 
Counts of Fos-and Jun B-immunopositive nuclei
The numbers of immunopositive nuclei (nuclei per mm 2 ) were estimated for striatal sections from control and d-fenfluramine-treated rats, using a standard transverse level, ϳ10 mm rostral to the interaural line. The analysis was carried out single-blind with a 10ϫ objective using an image analysis system (Biocom, Les Ulis, France). A horizontal strip through the middle of the caudoputamen was chosen as the sample area for all sections (Moratalla et al., 1996a) . Before counting, threshold levels were set empirically by independent observers to allow detection of nuclei stained with moderate to high intensity, with suppression of lightly stained nuclei.
Semiquantitative RT-PCR analysis of c-fos mRNA expression
The expression of mRNA for c-fos was assessed by reverse transcription and amplified cDNA by semiquantitative PCR performed according to Kerdine et al. (1996) . Striatal homogenates from three rats were pooled and total cellular RNA was isolated by acid guanidinium thiocyanate/phenol/chloroform extraction (Chomczynski and Sacchi, 1987) . Levels of c-fos transcripts were normalized to those of a rat ␤-actin probe. cDNA was synthesized in 20-l reactions containing 1 g of cellular RNA and 25 M oligo(dT) 15 primer (Bioprobe Systems, Montreuil, France), 50 mM dNTP, 40 mM sodium pyrophosphate, 62.5 mM Tris-HCl, pH 8.3, 8 U of spermidine (Promega), 25 U of RNase inhibitor (Promega), and 5 U of AMV-reverse transcriptase (Promega). Following a 90-min incubation at 42°C, fractions of the reverse transcription products were obtained following reverse transcription of 2 g of the total cellular mRNA. The DNA amplification was carried out in 1ϫ PCR buffer supplemented with 800 M dNTP, 0.50 M each of 5Ј-and 3Ј-specific primers (custom-synthesized; Bioprobe), and 2 U of Taq polymerase (HighTaq, Bioprobe) in a final volume of 100 l. The mixture was overlaid with mineral oil and amplified in 30 cycles in a thermal cycler (Hybaid Thermal Reactor TR 1L). The rat primer sequences from Bioprobe were as follows: ␤-actin sense, 5Ј-TTCCT-GGGTAAGTTGTAGTC-3Ј; ␤-actin antisense, 5Ј-AGCACT-GTGTTGGCATAGAG-3Ј; c-fos sense, 5Ј-GGAGCTGACA-GATACGCTCCA-3Ј; c-fos antisense, 5Ј-AATGTTCTT-GACGGCTCCA-3Ј. The lengths of cellular amplicon for ␤-actin and c-fos were 190 and 298 bp, respectively. The cycling conditions were 2 min at 95°C for the denaturation, 2 min at 57°C for annealing, and 2 min at 72°C for the elongation. The PCR amplification was terminated by 10 min at 72°C for the final elongation. Then a 1:20 dilution of the PCR products was used for separation of cellular amplicons by 1% agarose gel electrophoresis in the presence of ethidium bromide. The intensity of specific bands on Polaroid negatives was quantified with a densitometry system (Computing Densitometer, Molecular Dynamics, Sunnyvale, CA, U.S.A.) and the corresponding software (Image Quant software). To correct for any variation in RNA content and cDNA synthesis in the different striatal homogenates, and to perform a relative quantification of specific mRNA levels, we used the relatively invariant ␤-actin mRNA as control. PCR amplifications of both cellular templates were run in parallel (Bouaboula et al., 1992) . Each level of c-fos mRNA was expressed as a percentage of ␤-actin mRNA expression calculated for each rat.
In the first RT-PCR experiment, rats were injected with a single dose of d-fenfluramine (10 mg/kg, i.p.) or saline (2 ml/kg, i.p.). Then total RNA was extracted from the caudoputamen 0.5, 1, 2, and 6 h after d-fenfluramine injection, and the extracted mRNA was converted to cDNA and amplified by RT-PCR. In the second RT-PCR experiment, rats received a range of d-fenfluramine doses (5, 10, 20, and 40 mg/kg, i.p.) or saline (2 ml/kg, i.p.), and RT-PCR analysis was performed on RNA isolated from the caudoputamen 30 min after the single drug injection. The c-fos and ␤-actin mRNA expression was then quantified with a densitometry system.
Measurement of striatal 5-HT, 5-hydroxyindole-3-acetic acid (5-HIAA), and dopamine levels in p-chloroamphetamine (PCA)-pretreated rats
To produce lesions of serotoninergic neurons, rats were injected intraperitoneally with PCA (7.5 mg/kg for 2 days and then 10 mg/kg for 3 days) and then were allowed to recover for 1 week (D'Amato et al., 1987; Bhat and Baraban, 1993) before the administration of either saline (2 ml/kg) or d-fenfluramine (40 mg/kg). Rats were perfused 2 h after the last drug administration for immunocytochemical examination of brain tissue or quickly decapitated for subsequent RNA or analytical studies. Dopamine uptake sites were also measured as described by Graybiel and Moratalla (1989) after the PCA treatment. Treatments for the seven groups of rats (four to six animals per group) are summarized in Table 1 .
Monoamine levels in the striatum of PCA-treated rats were measured and compared with controls following methods previously described (Gardier et al., 1994) . After decapitation, brains were quickly removed, and the caudoputamen was removed (Glowinski and Iversen, 1966 ) and kept at Ϫ70°C for subsequent assays of 5-HT, its major metabolite 5-HIAA, and dopamine. On the day of analysis, tissue samples were thawed, weighed, and sonicated in a perchloric acid medium (0.2 M HClO 4 ) containing 0.1% EDTA, 0.1% Na 2 S 2 O 5 , and 0.1% L-cysteine as antioxidant. The tissue homogenates (standardized to 100 mg of wet tissue/ml) were then centrifuged at 17,000 g for 15 min. 5-HT and 5-HIAA were measured using a liquid chromatography system coupled to an electrochemical detector.
Statistics
Statistical analyses were performed with StatView 4.02 (Abacus Concepts, Inc, Berkeley, CA, U.S.A.). Statistical analyses of group differences were carried out for the quantification of immunopositive nuclei as well as for concentrations of biogenic amines in rat brain homogenates expressed in nanograms per gram of wet weight tissue. Values are means Ϯ SEM for five to eight determinations. A two-way ANOVA was used to establish a significant interaction between pretreatment (PCA, SCH 23390, or methiothepin) and treatment (saline or d-fenfluramine). These analyses were performed by using oneor two-way ANOVA followed by Scheffé's F tests for comparison of pairs of treatments when appropriate. Statistical significance was considered when p Ͻ 0.05.
RESULTS
Expression of Fos-like and Jun B-like proteins in the striatum following d-fenfluramine treatment: comparison with cocaine
Fos-like and Jun B-like proteins were distributed in a characteristic pattern in the caudoputamen following dfenfluramine treatment. As shown for Fos expression in Fig. 1B , the most intense expression was in the central and centromedial parts of the caudoputamen. Only low levels of induction occurred laterally. This general distribution pattern closely resembled that evoked by acute exposure to cocaine (Fig. 1A) . At more caudal levels, Fos-positive and Jun B-positive nuclei in the caudoputamen appeared mainly in localized dorsal and ventral parts of this area, again paralleling distributions for cocaine induction (data not shown; Graybiel et al., 1990; Moratalla et al., 1993) .
Counts of immunopositive nuclei in rats prepared for the dose-response study showed that the induction of Fos in the striatum was dose-dependent, whereas that of Jun B was not (Fig. 2) . Fos expression increased steadily for d-fenfluramine doses from 5 to 40 mg/kg, whereas Jun B expression reached a maximum at the lowest dose tested (10 mg/kg). Higher doses of d-fenfluramine did not increase Jun B expression further. 
Semiquantitative RT-PCR analysis of c-fos mRNA expression in the striatum of d-fenfluramine-treated rats
To analyze the induction of c-fos, rats were injected with a single dose of d-fenfluramine (5, 10, 20, or 40 mg/kg, i.p.) or with saline (2 ml/kg), and total RNA was extracted from the striatum 1 h after treatment. The results of RT-PCR (Fig. 3A) demonstrated that c-fos mRNA expression increased in a dose-dependent manner in the range of d-fenfluramine doses studied. To determine the time course of this induction, a second set of rats was injected intraperitoneally with a single dose (2 ml/kg) of 10 mg/kg d-fenfluramine or saline, and total RNA was extracted from the caudoputamen 0.5, 1, 2, and 6 h after the injections. RT-PCR analysis (Fig. 3B) showed that the d-fenfluramine-induced c-fos mRNA expression was transiently increased, reaching its maximum at 0.5 h after d-fenfluramine injection and then returning to control levels by 6 h.
Effects of PCA on Fos-like proteins in the striatum of d-fenfluramine-treated rats (40 mg/kg for 2 h)
To assess the role of the 5-HT system in mediating the effects of d-fenfluramine on the expression of Fos-like proteins in the striatum, we administered PCA to induce degeneration of 5-HT-containing fibers (Fig. 4) . To ensure that the PCA treatment targeted principally 5-HTcontaining nerve terminals relative to dopamine-containing nerve terminals, we assessed the effects of PCA treatment on 5-HT and dopamine metabolism by measuring striatal 5-HT, 5-HIAA, and dopamine content in a set of rats treated with a single 40 mg/kg dose of dfenfluramine or with saline 1 week after PCA treatment (Table 2) . PCA pretreatment decreased 5-HT and 5-HIAA levels in the striatum to 18 and 10% of the respective control values measured in saline-treated rats. Similar results were obtained in rats treated with the combination PCA ϩ d-fenfluramine. This combined treatment decreased 5-HT and 5-HIAA levels in the striatum to 12 and 21% of the respective control values measured in saline-treated rats, while decreasing dopamine levels to 72%. These results demonstrate that our 
FIG. 4.
Numbers of nuclei expressing Fos-like protein in the dorsomedial part of the caudoputamen counted bilaterally in single sections, from rats pretreated for 5 days with PCA (7.5 mg/kg/day for 3 days and 10 mg/kg/day the next 2 days), given a 7-day washout period, and then given either saline (2 ml/kg) or d-fenfluramine (d-fen; 40 mg/kg, i.p.). Animals were perfused 2 h after the last injection. Data are expressed as the number of cells per mm 2 (means Ϯ SEM for n ϭ 4 -5 determinations per group). ***p Ͻ 0.001, significantly different from controls.
PCA treatment targeted mainly the serotoninergic rather than the dopaminergic terminals. Thus, pretreatment with PCA markedly decreased the expression of Fos-like protein following d-fenfluramine treatment compared with the expression in saline-pretreated controls.
Effect of methiothepin on the inducibility of Fos-like and Jun B-like protein expression in the striatum following d-fenfluramine treatment
Pretreatment with the nonselective 5-HT 1 receptor antagonist, methiothepin (10 mg/kg), produced a small reduction in the number of cell nuclei that express Fos and Jun B proteins in the striatum following d-fenfluramine (20 mg/ kg) administration. This reduction was ϳ18% for Fos ( Fig.  5A ) and was statistically significant and ϳ12% for Jun B (Fig. 5B) . Similar effects were obtained with the highest dose of d-fenfluramine tested (40 mg/kg). Methiothepin pretreatment, however, completely blocked the d-fenfluramine-induced expression of Fos-like and JunB-like proteins in the neocortex (data not shown). Rats treated with methiothepin alone did not exhibit significant differences in the expression of Fos-like and JunB-like proteins in the brain regions studied when compared with control animals treated with vehicle.
Effect of SCH 23390 on the inducibility of Fos-like and Jun B-like protein expression in the striatum following d-fenfluramine treatment
Pretreatment with low doses (0.3 mg/kg, i.p.) of the D 1 -class selective dopamine receptor antagonist, SCH 23390, partially blocked the expression of Fos-like (Fig. 5A) and Jun B-like (Fig. 5B) proteins by dfenfluramine (20 mg/kg) in the striatum. SCH 23390 produced a significant reduction in the number of cell nuclei that express Fos-like (58%; Fig. 5A ) and Jun B-like proteins (40%; Fig. 5B ) in the striatum following d-fenfluramine. This partial inhibition was still present at the 40 mg/kg dose of d-fenfluramine (data not shown). Control rats treated with saline vehicle only showed very small Fos-like and Jun B-like protein expression in the striatum and other brain regions. Administration of SCH 23390 alone did not affect Fos expression in the striatum, but slightly reduced Jun B expression.
Phenotypes of striatal neurons expressing Fos-like proteins in response to d-fenfluramine
To determine the phenotypes of the striatal neurons expressing Fos/Jun B following treatment with d-fenflur- (6) A single dose of d-fenfluramine (40 mg/kg, i.p.) or saline (2 ml/kg) was administered to rats. These animals were pretreated with either five doses (24-h interval) of saline or PCA (7.5 mg/kg for 2 days and then 10 mg/kg for the next 3 days) 1 week before d-fenfluramine administration. Animals were killed 2 h after the last drug injection as described in the text. Concentrations in brain homogenates are expressed in ng/g of wet tissue. Values are means Ϯ SEM. Numbers of determinations are in parentheses. ND, not determined.
a p Ͻ 0.001 when compared with saline by using a one-way ANOVA followed by Student's t test. amine (20 mg/kg), we carried out dual staining for Fos and neuropeptide markers for the two principal classes of striatal projection neurons (dynorphin and enkephalin), and also for a marker (NADPH-diaphorase) of one class of striatal interneurons (Fig. 6) . Of the Fos-positive nuclei counted, 22 Ϯ 1.2% (mean Ϯ SEM for 24 determinations) were also stained for dynorphin ( Fig. 6C and D) . By contrast, only 7.9 Ϯ 1.1% (mean Ϯ SEM for 30 determinations) of Fos-positive nuclei expressed enkephalin-like immunoreactivity ( Fig. 6A  and B) . Numerous NADPH-diaphorase-stained neurons with Fos-positive nuclei (ϳ6%) were also found in the striatum following d-fenfluramine administration. Fewer than 0.25% of the NADPH-diaphorasepositive neurons contained Fos-positive nuclei in saline-treated control rats (Fig. 6E) . Expression of Jun B was localized in the same types of neurons that expressed Fos (data not shown).
DISCUSSION
The results reported here suggest that d-fenfluramine, a drug that selectively releases 5-HT and blocks its reuptake, triggers transcription factor gene expression in the striatum as an indirect consequence of interactions between striatal 5-HT and dopamine circuitries. the expression of Fos-like proteins. Furthermore, the d-fenfluramine-induced IEG expression in the striatum depended not only on 5-HT (including 5-HT 1 receptors), but also partially on D 1 -class dopamine receptors. We suggest that the effects of a single administration of d-fenfluramine on the striatum result from interactions between cellular events transduced by 5-HT and dopamine receptors. An attractive possibility is that d-fenfluramine elicits the release of endogenous 5-HT, which in turn stimulates striatal dopamine release leading to the gene induction in the striatum.
Our work confirms and extends previous studies showing that d-fenfluramine induces c-fos expression in the striatum. In addition, we report the novel finding that this drug also induces concomitantly the expression of Jun B. This finding is important, inasmuch as it is known that different Fos and Jun proteins selectively interact to form heterodimeric complexes that activate or inhibit the expression of specific genes. Therefore, the selective activation of certain c-Fos-like and Jun B-like proteins by d-fenfluramine implies that proteins of these two classes can interact in regulating specific target genes induced by this drug. Similar coactivation of Fos-and Jun-family proteins has been demonstrated for treatments with typical neuroleptics (Simpson and Morris, 1994) and cocaine (Moratalla et al., 1993 (Moratalla et al., , 1996a .
Treatment with d-fenfluramine induced a dose-dependent expression of Fos-like protein in the striatum (5-40 mg/kg, i.p.). This response was more intense in the middle and dorsomedial caudoputamen and, at caudal levels, dorsal and ventral zones. d-Fenfluramine also induced the expression of Jun B-like proteins in the striatum, and the similarity between the patterns of distribution of Fos-and Jun B-immunoreactive neurons suggests that the regulation of the two genes occurs in the same neurons. However, we did not find a doseresponse effect of d-fenfluramine on the expression of Jun B-like proteins in the striatum within the range of doses tested. Therefore, the response of Jun B was different from that of Fos. Our immunohistochemical findings for c-fos are in good agreement with our evidence that c-fos mRNA is induced transiently in the striatum following a single d-fenfluramine administration in a dose-dependent manner over doses from 5 to 40 mg/kg.
Our evidence strongly suggests that the capacity of d-fenfluramine to induce the expression of Fos-like and Jun B-like proteins in the striatum is partially dependent on activation of D 1 -class dopamine receptors. We accumulated two different sets of data in support of this assertion. First, we observed that the d-fenfluramineinduced IEG expression is partially antagonized by low doses of SCH 23390. Higher doses of this drug also produced a partial blockade of striatal IEG expression (data not shown). Second, we found that the Fos-like protein is colocalized in striatal neurons with dynorphin immunoreactivity, whereas most of the enkephalin-positive neurons of the striatum did not show Fos staining. D 1 -class dopamine receptors are thought to be preferentially expressed on the projection neurons coexpressing the neuropeptides dynorphin (Xu et al., 1994; Moratalla et al., 1996a) and substance P (Gerfen et al., 1990) , whereas D 2 -class dopamine receptors are strongly expressed by projection neurons coexpressing the neuropeptide enkephalin (Gerfen et al., 1990) . Results similar to the present findings have been obtained recently with the racemic mixture d,l-fenfluramine showing that it induces a specific expression of Fos-like proteins within the striatum, which was partially blocked by pretreatment with higher doses of SCH 23390 (Torres and Rivier, 1993; Rouillard et al., 1996; Guerra et al., 1998) . We used two different doses for SCH 23390 and obtained similar results with each, but only the lower dose (0.2 mg/kg) is thought to be selective for D 1 -class dopamine receptors and to avoid the interactions with 5-HT 2 receptors found for higher doses (Bischoff et al., 1986) .
The dopamine D 1 -class receptor-mediated effect of d-fenfluramine is not likely to reflect a direct action on dopamine or 5-HT receptors, because neither d-fenfluramine nor its main active metabolite, d-norfenfluramine, binds to any particular 5-HT or dopamine receptor subtype with high affinity (Samanin and Garattini, 1990) . However, we cannot exclude the possibility that another receptor-mediated mechanism of action could be involved, especially at the high doses (20 and 40 mg/kg) used in this study.
Destruction of serotoninergic projection systems by PCA, which depleted striatal tissue 5-HT levels by 88% and slightly reduced those of dopamine (by 28%), totally suppressed increases in Fos-like protein expression induced in the striatum by d-fenfluramine. This result suggests that the integrity of the serotoninergic system is a necessary requirement for the induction of Fos expression by d-fenfluramine, in agreement with the results of Guerra et al. (1998) . Taken together with the only partial blockade of d-fenfluramine induction of striatal Fos and Jun B expression by a low dose of the D 1 -class dopamine receptor antagonist, SCH 23390, these data suggest that the Fos and Jun B protein expression is related to the activation of serotoninergic neurons but, in addition, depends on dopamine active at D 1 -preferring sites.
At least three alternative mechanisms might account for our findings. First, a synergism between striatal 5-HT and dopamine circuitries may have occurred at the level of the striatum to promote the activation of IEG expression. Such a direct effect would be consistent with data obtained by in vivo microdialysis demonstrating that in anesthetized rats, d-fenfluramine can directly release striatal dopamine by a Ca 2ϩ -dependent, tetrodotoxin-sensitive mechanism independent of striatal 5-HT itself, and that local administration of 5,7-dihydroxytryptamine into the dorsal raphe nucleus did not modify this effect (De Deurwaerdère et al., 1995) . This hypothesis is also consistent with the fact that some 5-HT receptor agonists can induce Fos expression through a direct action on striatal cell bodies and that stimulation of dopamine receptors positively linked to adenylate cyclase plays a permissive role in this effect .
Alternatively, the effects of d-fenfluramine in the striatum may have been indirect, reflecting activation of the massive glutamatergic corticostriatal system (McGeorge and Faull, 1989) . Evidence suggests that L-glutamate can activate the release of dopamine in the striatum. The activation of L-glutamate receptors located on dopaminergic and serotoninergic axon terminals in the striatum could also modulate the d-fenfluramine-induced dopamine and 5-HT release, and influence effects of d-fenfluramine on striatal Fos expression. It has been suggested that D 1 -class dopamine receptors and glutamate NMDA postsynaptic receptors have combinatorial actions in mediating the effects of fenfluramine on striatal Fos expression (Torres and Rivier, 1993) .
A third possibility, favored here, is that the involvement of the dopaminergic system in inducing striatal IEG expression in response to the d-fenfluramine is mostly an indirect consequence of d-fenfluramine's ability to activate 5-HT release from serotoninergic axon terminals in the substantia nigra. 5-HT-containing axons have been shown to project from the dorsal raphe nucleus to the substantia nigra pars compacts and to modulate the dopaminergic nigrostriatal pathway (Van der Kooy and Hattori, 1980; Soubrié et al., 1984; Yadid et al., 1994) . Furthermore, 5-HT released in the striatum by d-fenfluramine may stimulate 5-HT receptors, which in turn could increase striatal dopamine release. Both 5-HT receptor agonists and fenfluramine facilitate striatal dopamine release (Benloucif and Galloway, 1991; Benloucif et al., 1993) , and an in vivo microdialysis study performed in freely moving rats has demonstrated directly that dfenfluramine has an indirect dopamine-releasing capacity via 5-HT release in the striatum at doses higher than 2.5 mg/kg i.p. (Balcioglu and Wurtman, 1998) . Given the converging lines of evidence obtained here with PCA pretreatment, with predominant d-fenfluramine-induced increases in Fos expression in the class of striatal projection neurons known to express D 1 -class dopamine receptors, we favor this third alternative.
We extended these results by showing that the striatal Fos and Jun B responses to d-fenfluramine (20 mg/kg) not only are partially blocked by pretreatment with a low dose of SCH 23390, but also are slightly decreased by prior administration of a nonselective 5-HT 1 receptor antagonist, methiothepin (10 mg/kg). This dose of methiothepin has been shown to be effective in blocking d-fenfluramine's effects on brain tissue levels of 5-HT as well as on extracellular 5-HT levels in the rat frontal cortex (Gardier et al., 1992) . Methiothepin is a nonselective 5-HT 1 receptor antagonist, but it displays high affinities for 5-HT 1A and 5-HT 1B receptor subtypes in rats (Engel et al., 1986) . 5-HT 1B receptors are concentrated within the striatum (Boulenguez et al., 1996) . Furthermore, the nonselective 5-HT 1A/1B receptor agonist, RU 24969, can induce the expression of Fos-like proteins within the rat striatum, thus reproducing the effects of d-fenfluramine, and the response to RU 24969 is not blocked by pretreatment with a selective 5-HT 1A receptor antagonist . Taken together with the fact that 5-HT 1A and 5-HT 2A/2C receptor antagonists fail to attenuate d-fenfluramine-induced Fos-like protein expression in the brain (Rouillard et al., 1996; Javed et al., 1998) , these data suggest that the response to methiothepin was mediated by the blockade of 5-HT 1B receptors. A comparison of the results we obtained with methiothepin and with SCH 23390 indicates, however, that the activation of 5-HT 1B receptors contributes only moderately to the d-fenfluramine-induced Fos expression in the striatum, whereas the activation of D 1 -class dopamine receptors is more important.
It is also remarkable that RU 24969 dose-dependently induces striatal Fos expression in mice in anatomical patterns similar to those induced by cocaine (Lucas et al., 1997 (Lucas et al., , 1998 ), as we have found for d-fenfluramine. The effect of RU 24969 was reduced in 5-HT 1B receptor knockout mice and was blocked completely in wild-type mice pretreated with the mixed 5-HT 1B/1D receptor antagonist GR 127935 (Lucas et al., 1997) . The Fos expression induced by fenfluramine was also reduced substantially in the brains of the 5-HT 1B receptor knockout mice (Lucas et al., 1998) . Destruction of 5-HT-containing axons by PCA pretreatment attenuates the increase in c-fos mRNA levels induced in the rat striatum by cocaine (Graybiel et al., 1990; Bhat and Baraban, 1993) and completely blocks Fos induction by d-fenfluramine. These results suggest that both d-fenfluramine and cocaine may induce c-fos expression by mechanisms depending conjointly on dopaminergic and serotoninergic systems, but in different proportions. Our findings show a striking parallel between d-fenfluramine and cocaine in many aspects of their IEG activation effects, including the general distribution of Fos-like protein expression in the caudoputamen and the prominence of the induction in dynorphin-positive projection neurons and NADPHdiaphorase-positive interneurons (Graybiel et al., 1990; Berretta et al., 1992; Moratalla et al., 1993 Moratalla et al., , 1996a . It has also been shown recently that both cocaine and fenfluramine induce the expression of Fos-like proteins in striatal neurons expressing the protein phosphatase inhibitor DARPP-32 (dopamine and cyclic AMP-regulated phosphoprotein), considered as a marker for neurons bearing D 1 -class dopamine receptors (Berretta et al., 1992; Torres and Rivier, 1994) . There is no evidence, however, that these effects lead to similar behavioral consequences in mammals. Cocaine suppresses appetite by inhibiting consumption of all the macronutrients and leads to hyperactivity and addiction; d-fenfluramine induces hypophagia by enhancing satiety and by inhibiting overconsumption of carbohydrates, decreases locomotion in mice and rats, does not possess abuse liability, and does not produce addiction in human. The functional and physiological significance of interactions between 5-HT and dopamine at the level of the induction of transcription factors in the striatum is unknown (Rouillard et al., 1996) .
